Viking Holdings Aktie
WKN DE: A40ANH / ISIN: BMG93A5A1010
25.07.2024 18:03:08
|
Why Viking Therapeutics Stock Is Skyrocketing Today
Shares of Viking Therapeutics (NASDAQ: VKTX) were skyrocketing 32.3% as of 11:21 a.m. ET on Thursday. The big gain came after the clinical-stage biopharmaceutical company provided its second-quarter update following the market close on Wednesday.Viking reported no revenue and a net loss of $22.3 million, or $0.20 per share, in Q2. However, the company's financial results weren't the big story in the quarterly update. Instead, investors were excited that Viking plans to advance its experimental obesity drug VK2735 into a phase 3 clinical study after receiving written feedback from a meeting with the U.S. Food and Drug Administration (FDA). Earlier this year, Viking announced overwhelmingly positive results from its phase 2 study of VK2735. Patients receiving the obesity drug achieved up to 13.1% placebo-adjusted mean weight loss after 13 weeks of treatment. Continue readingWeiter zum vollständigen Artikel bei MotleyFool

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
Nachrichten zu Viking Holdings Ltd Registered Shsmehr Nachrichten
10.03.25 |
Ausblick: Viking legt Quartalsergebnis vor (finanzen.net) |
Analysen zu Viking Holdings Ltd Registered Shsmehr Analysen
Aktien in diesem Artikel
Viking Holdings Ltd Registered Shs | 34,96 | -8,82% |
|
Viking Therapeutics Inc | 20,16 | -8,24% |
|